Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 9/20 | 0.51 |
| ▸ | CA2 | P00918 | 9/20 | 0.51 |
| ▸ | CA12 | O43570 | 6/20 | 0.51 |
| ▸ | CA9 | Q16790 | 6/20 | 0.51 |
| ▸ | STK17B | O94768 | 1/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL569251 | 0.90 | TDP1 (0.74) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL6245478 | 0.88 | TDP1 (0.56) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL3020258 | 0.86 | TDP1 (0.81) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL1629516 | 0.85 | TDP1 (0.62) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL3910909 | 0.84 | TDP1 (0.67) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL1557057 | 0.84 | TDP1 (0.67) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL137629 | 0.84 | TDP1 (0.85) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL5162656 | 0.84 | TDP1 (0.85) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL134329 | 0.84 | TDP1 (0.85) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL3025184 | 0.84 | TDP1 (0.85) | TDP1MEN1GAAKMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| CN-109053523-B | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-111643496-A | Methods of using MEK inhibitors | 埃克塞利希斯股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS, INC. | 2020-01-30 | — | — | US | disclosed |
| CN-110668988-A | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| CN-104892582-B | Azetidine as the mek inhibitor for treating proliferative disease | 埃克塞利希斯股份有限公司 | 2019-09-27 | — | — | CN | disclosed |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2019-05-16 | — | — | US | disclosed |
| CN-109053523-A | Azetidine as the mek inhibitor for treating proliferative disease | 埃克塞利希斯股份有限公司 | 2018-12-21 | — | — | CN | disclosed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20110263558-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | EXELIXIS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-1934174-B1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS INC (US) | 2011-04-06 | — | — | EP | disclosed |
| US-7915250-B2 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | EXELIXIS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100249096-A1 | anticarcinogenic agent; 1-({4-[(2-fluoro-4-iodophenyl)amino]-3-thienyl}carbonyl)azetidin-3-amine | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2101759-A1 | METHODS OF USING MEK INHIBITORS | Exelixis, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | BRAF, NRAS, MAP3K20 | TDP1 1707/4885MEN1 565/4885GAA 1407/4885 |
| US-20100249096-A1 | anticarcinogenic agent; 1-({4-[(2-fluoro-4-iodophenyl)amino]-3-thienyl}carbonyl)azetidin-3-amine | NRAS, BRAF, KRAS | TDP1 1106/4885MEN1 872/4885GAA 2446/4885 |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | NRAS, BRAF, KRAS | TDP1 1038/4885MEN1 1722/4885GAA 1845/4885 |
| US-20110263558-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | NRAS, BRAF, KRAS | TDP1 2504/4885MEN1 164/4885GAA 607/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | TDP1 2192/4885MEN1 425/4885GAA 2414/4885 |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | BRAF, NRAS, MAP3K20 | TDP1 1707/4885MEN1 565/4885GAA 1407/4885 |
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | TDP1 1707/4885MEN1 565/4885GAA 1407/4885 |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, MAP3K20 | TDP1 1707/4885MEN1 565/4885GAA 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.